title: [Stem cell treatment of autoimmune disease].
abstract: Over 1,500 patients world wide have received a hematopoietic stem cell transplant (HSCT) as treatment for a severe autoimmune disease. Most of these have been autologous and mostly have occurred in the past 15 years. Over 1,000 of these have been registered in the European Group for Bone Marrow Transplantation (EBMT) and European League Against Rheumatism (EULAR) combined data base. A recent retrospective analysis of 900 patients (1) showed that the majority had multiple sclerosis (n = 345) followed by systemic sclerosis (n = 175), systemic lupus erythematosus (n = 85), rheumatoid arthritis (n = 89), juvenile idiopathic arthritis (n = 65) and idiopathic cytopenic purpura (n = 37). An overall 85 % 5-year-survival and 43 % progression-free survival was seen, with 100-day-transplant-related-mortality (TRM) ranging between 1 % (rheumatoid arthritis) and 11 % (systemic lupus erythematosus and juvenile idiopathic arthritis). Around 30 % of patients in all disease subgroups had a complete response, often durable despite full immune reconstitution. In many, e. g. systemic sclerosis, morphological improvement such as reduction of skin collagen and normalisation of microvasculature was documented, beyond any predicted known effects of intense immunosuppression alone. The high TRM was in part related to conditioning intensity, comorbidity and age, and the final risk/benefit assessment will be made after the results of the three randomised propective clinical trials are known. [nl]Recently, multipotent mesenchymal stromal cells have been tested in various autoimmune diseases, exploiting their immune modulating properties and apparent low acute toxicity. Despite encouraging small phase I/II studies, no positive data from randomised, prospective studies are as yet available in the peer reviewed literature.
authors.affiliation: Rheumatologische Universitätsklinik, Basel.
authors.forename: T
authors.initials: T
authors.lastname: Daikeler
authors.forename: A
authors.initials: A
authors.lastname: Tyndall
mesh_terms: D001171:Arthritis, Juvenile / Q000401:mortality / Q000628:therapy; D001172:Arthritis, Rheumatoid / Q000401:mortality / Q000628:therapy; D001327:Autoimmune Diseases / Q000401:mortality / Q000628:therapy*; D018849:Controlled Clinical Trials as Topic; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000401:mortality / Q000628:therapy; D045164:Mesenchymal Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods; D009103:Multiple Sclerosis / Q000401:mortality / Q000628:therapy; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000401:mortality / Q000628:therapy; D016032:Randomized Controlled Trials as Topic; D012595:Scleroderma, Systemic / Q000628:therapy; D033581:Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods; D015996:Survival Rate